The CD19-targeted CAR-T cell therapy system is a new and effective immunotherapy for the treatment of blood cancers. This personalized cellular therapy is produced by genetically reprogramming the patient's own T cells to recognize the surface antigen CD19. CD19 is a highly expressed target, especially in B cell-derived malignancies (such as Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma), which allows the treatment to selectively recognize and eliminate cancer cells. Our product is based on a modern CAR-T platform developed to deliver a long-lasting and powerful therapeutic effect. This innovative approach aims to be a new source of hope, especially for recurrent or treatment-resistant patients.